Interaction of St John's wort with conventional drugs: Systematic review of clinical trials

British Medical Journal

Volumn 329, Issue 7456, 2004, Pages 27-30

  Mills, Edward ^a,f   Montori, Victor M ^b   Wu, Ping ^c   Gallicano, Keith ^d   Clarke, Mike ^e   Guyatt, Gordon ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b Mayo Clinic   (United States)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d Watson Laboratories   (United States)

^e UK COCHRANE CENTRE   (United Kingdom)

^f MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG; HYPERICUM PERFORATUM EXTRACT;

AREA UNDER THE CURVE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG RESEARCH; DRUG SCREENING; HEALTH CARE; HERBAL MEDICINE; HUMAN; HYPERICUM PERFORATUM; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 3042802316     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.329.7456.27     Document Type: Review

References (29)

1. Thomas KJ, Nicholl JP, Coleman P. Use and expenditure on complementary medicine in England: a population based survey. Complement Ther Med 2001;9:2-11.
2. Altman DG, Gardner MJ. Means and their differences. In: Altman DG, Bryant TN, Gardner MJ, eds. Statistics with confidence. Bristol: BMJ Publishing, 2000:28-35.
3. Food and Drug Administration. In vivo drug metabolism/drug interaction studies - study design, data analysis, and recommendations for dosing and labeling. 1999. www.fda.gov/cber/gdlns/metabol.pdf (accessed 20 May 2004)
4. Johne A, Schmider J, Brockmoller J, Stadelmann AM, Stormer E, Bauer S, et al. Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St John's wort (Hypericum perforatum). J Clin Psychopharmacol 2002;22:46-54.
5. Mathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A. Effects of St John's wort on irinotecan metabolism. J Natl Cancer Inst 2002;94:1247-9.
6. Bauer S, Stormer E, Johne A, Kruger H, Budde K, Neumayer HH, et al. Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients. Br J Clin Pharmacol 2003;55:203-11.
7. Mai I, Stormer E, Bauer S, Kruger H, Budde K, Roots I. Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol Dial Transplant 2003;18:819-22.
8. Hall SD, Wang Z, Huang SM, Hamman MA, Vasavada N, Adigun AQ, et al. The interaction between St John's wort and an oral contraceptive. Clin Pharmacol Ther 2003;74:525-35.
9. Wang Z, Hamman MA, Huang SM, Lesko LJ, Hall SD. Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther 2002;71:414-20.
10. Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001;70:317-26.
11. Roby CA, Dryer DA, Burstein AH. St John's wort: effect on CYP2D6 activity using dextromethorphan-dextrorphan ratios. J Clin Psychopharmacol 2001;21:530-2.
12. Wenk M, Todesco L, Krahenbuhl S. Effect of St John's wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females. Br J Clin Pharmacol 2004;57:495-9.
13. Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich M, Roots I. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther 1999;66:338-45.
14. Burstein AH, Horton RL, Dunn T, Alfaro RM, Piscitelli SC, Theodore W. Lack of effect of St John's wort on carbamazepine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 2000;68:605-12.
15. Sugimoto K, Ohmori M, Tsuruoka S, Nishiki K, Kawaguchi A, Harada K, et al. Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 2001;70:518-24.
16. Markowitz JS, deVane CL, Boulton DW, Carson SW, Nahas Z, Risch SC. Effect of St John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Life Sci 2000;66:PL133-9.
17. Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J. Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial. Br J Clin Pharmacol 2003;56:683-90.
18. Wang LS, Zhou G, Zhu B, Wu J, Wang JG, El-Aty Am AA, et al. St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharmacol Ther 2004;75:191-7.
19. Morimoto T, Kotegawa T, Tsutsumi K, Ohtani Y, Imai H, Nakano S. Effect of St John's wort on the pharmacokinetics of theophylline in healthy volunteers. J Clin Pharmacol 2004;44:95-101.
20. Durr D, Stieger K, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K. St John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000;68:598-604.
21. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St John's wort. Lancet 2000;355:547-8.
22. Jiang X, William KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, et al. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2004;57:592-9.
23. Hebert MF, Park JM, Chen YL, Akhtar S, Larson AM. Effects of St John's wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 2004;44:89-94.
24. Markowitz JS, Donovan JL, DeVane CL, Taylor RM, Ruan Y, Wang J, et al. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003;290:1500-4.
25. Dresser GK, Schwarz UI, Wilkinson GR, Kim RB. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin Pharmacol Ther 2003;73:41-50.
26. Hammerness P, Basch E, Ulbricht C, Barrette EP, Foppa I, Basch S, et al. St John's wort: a systematic review of adverse effects and drug interactions for the consultation psychiatrist. Psychosomatics 2003;44:271-82.
27. Markowitz JS, deVane CL. The emerging recognition of herb-drug interactions with a focus on St John's wort (Hypericum perforatum). Psychopharmacol Bull 2001;35:53-64.
28. Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P. St John's wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 2002;54:349-56.
29. Draves AH, Walker SE. Analysis of the hypericin and pseudohypericin content of commercially available St John's wort preparations. Can J Clin Pharmacol 2003;10:114-8.